Johnson & Johnson ：Degrader-Antibody Conjugates (DACs) are an emerging field with significant potential.
Dualitybio：Completed IPO coaching and proposes listing on the STAR Market.
Hengrui ：HS-10568 marketing application submitted
Sanofi ：Riliprubart’s Phase III MOBILIZE Study (NCT06290128) to be Terminated
Laekna：LAE118 Exclusively Licensed in $527M+ Deal with Vasque Bio
Zelgen ：PD-1/TIGIT Bispecific Antibody ZG005 in Combination with Bevacizumab for First-Line Treatment of Advanced Hepatocellular Carcinoma: Phase II Clinical Data Presented
Mabworks ：Obinutuzumab beta approved for marketing in China.
Henlius ：Hetronifly®Serplulimabreceived marketing approval
How much does HIBRUKA (Orelabrutinib Tablets) Cost& price without insurance in China?
How much does Tyvyt (Sintilimab Injection) Cost& price without insurance in China?
